These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3022372)

  • 1. [Severe electrolyte disorders during the therapy of heart failure with the therapy of heart failure with the ACE-inhibitor enalapril].
    Hess B; Keusch G; Neftel K; Margelist F; Bansky G
    Schweiz Med Wochenschr; 1986 Sep; 116(39):1331-6. PubMed ID: 3022372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Severe complications during enalapril therapy for heart insufficiency].
    Wieland T; Stäubli M
    Schweiz Med Wochenschr; 1988 Dec; 118(48):1789-92. PubMed ID: 2849806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Electrolyte abnormalities and metabolic acidosis in two Duchenne muscular dystrophy patients with advanced congestive heart failure].
    Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
    Rinsho Shinkeigaku; 2000 May; 40(5):439-45. PubMed ID: 11002725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrolyte disturbances in patients with chronic heart failure--clinical, evolutive and therapeutic implications.
    Costache II; Cimpoeşu D; Petriş O; Petriş AO
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):708-13. PubMed ID: 23272514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature.
    Izzedine H; Fardet L; Launay-Vacher V; Dorent R; Petitclerc T; Deray G
    Clin Pharmacol Ther; 2002 Jun; 71(6):503-7. PubMed ID: 12087354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management.
    Packer M; Kessler PD; Gottlieb SS
    Postgrad Med J; 1986; 62 Suppl 1():179-82. PubMed ID: 3022272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of angiotensin converting enzyme inhibitors in heart failure: a clinician's guide to minimizing azotemia and diuretic-induced electrolyte imbalances.
    Weinberg MS
    Clin Ther; 1993; 15(1):3-17; discussion 2. PubMed ID: 8458051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors.
    Oster JR; Materson BJ
    Arch Intern Med; 1992 Apr; 152(4):704-10. PubMed ID: 1558426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ACE-inhibition on renal function in severe congestive heart failure.
    Swedberg K
    Z Kardiol; 1991; 80 Suppl 2():50-4. PubMed ID: 2024543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.
    Hasford J; Bussmann WD; Delius W; Köpcke W; Lehmann K; Weber E
    Z Kardiol; 1991; 80 Suppl 2():21-7. PubMed ID: 2024540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
    Vizir VA; Berezin AE
    Ter Arkh; 2002; 74(1):52-5. PubMed ID: 11878061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.
    Daphnis E; Stylianou K; Alexandrakis M; Xylouri I; Vardaki E; Stratigis S; Kyriazis J
    Nephron Clin Pract; 2007; 106(4):c143-8. PubMed ID: 17596722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to diuretic therapy and electrolyte imbalance in congestive heart failure.
    Cody RJ; Pickworth KK
    Cardiol Clin; 1994 Feb; 12(1):37-50. PubMed ID: 8181024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
    Dzau VJ
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):74-80. PubMed ID: 3037893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia.
    Burnakis TG; Mioduch HJ
    Arch Intern Med; 1984 Dec; 144(12):2371-2. PubMed ID: 6391404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kalemia during combined therapy with an angiotensin converting enzyme inhibitor and a potassium-sparing diuretic.
    Mooser V; Waeber G; Bidiville J; Waeber B; Nussberger J; Brunner HR
    J Clin Hypertens; 1987 Dec; 3(4):510-3. PubMed ID: 2839627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A patient with severe hyperkalaemia -- an emergency after RALES].
    Nürnberger J; Daul A; Philipp T
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.